Forum Markets, Incorporated · NASDAQ:FRMM
Forum Markets — KBL Merger Corp. IV — SPAC Merger (May 2019)
27 slides from Forum Markets's SPAC merger presentation, May 16, 2019
Slide 1: Corporate Presentation May 2019
CORPORATE PRESENTATION MAY 2019
Slide 2: Disclaimer
5 CANNBIORX DISCLAIMER ‘The information contained herein is being provided to you in connection with, and has been prepared for use only in connection with, the private placement (the “Placement”) of securities (the "Securities”) of KBL Merger Corp. IV (the “Company”). The Securities have not been r
Slide 3: Chronic Inflammation Has Huge Unmet Needs
CHRONIC INFLAMMATION HAS HUGE UNMET NEEDS CANNBIORx ADDRESSES MANY OF THESE PROBLEMS Mission To develop novel drugs, including man-made cannabinoids, that fulfill unmet needs in inflammatory diseases and fibrosis using the expertise of three founding luminaries in the therapeutics field who created
Slide 4: Chronic Inflammation Has Huge Unmet Needs: CannBioRx Addresses These Problems
CANNBIORX CHRONIC INFLAMMATION HAS HUGE UNMET NEEDS | CANNBIORx ADDRESSES THESE PROBLEMS ourPRionivies = PRIORITIES Market Size + Musculoskeletal (shoulder, knee, hands) >100 million affected globally’ “é + Neuropathic id + other drug in novel formulation < | Psoriatic artis = " Ze ‘Treatment - earl
Slide 5: Chronic Inflammation Has Huge Unmet Needs II
CHRONIC INFLAMMATION HAS HUGE UNMET NEEDS II ADDITIONAL AREAS OF POTENTIAL FOCUS Market Size MULTIPLE SCLEROSIS « Paralysis, muscle spasm, weakness, eye problems progressing to disability + Affects more than 2. million people globally" $23 bn (2018)? in novel formulation + Acute pain, joint damage,
Slide 6: KBL/CannBioRx Investment Rationale
KBL/CANNBIORX INVESTMENT RATIONALE Attractive valuat yn compared to comparable companies Unique investment at intersection of the cannabis and biotech industries Proven capacity to complete clinical trials quickly and efficiently using UK and then worldwide facilities Expertise in repurposing drugs
Slide 7: First-in-Class Therapeutics for Inflammation and Fibrosis
FIRST-IN-CLASS THERAPEUTICS FOR INFLAMMATION AND FIBROSIS Science team led by 3 therapeutics pioneers from 3 great university centers - University of Oxford, Hebrew University, Stanford Medical Center Phase 2b/3 Clinical Stage Program for Dupuytren’s contracture, recruitment in progress Developing 3
Slide 8: Co-Founded by Pioneers of Medical Science
CO-FOUNDED BY 3 PIONEERS OF MEDICAL SCIENCE Prof Sir Marc Feldmann Discoverer and Pioneer of Anti-TNF Therapy + University of Melbourne, Walter & Eliza Hall Institute, Kennedy Institute, University of Oxford ‘Analysis of human rheumatoid synovium led to anti-TNF therapy, world’s biggest drug class,
Slide 9: Management Team
MANAGEMENT TEAM + / Dr Marlene Krauss CEO Harvard Business School, Harvard Medical School, Cornell University + Assistant Prof of Ophthalmology (retinal surgery) - NY Hospital CEO of 4 SPACS and 3 VC Funds (Investors: Novartis and Allianz) Invested over $1 billion in early and mid stage companies in
Slide 10: CannBioRx Team
CANNBIORX TEAM WORLD CLASS TEAM: COMBINED WITH: SCIENTISTS WHO HEALTHCARE INVESTORS SUCCESSFULLY DEVELOPED WHOSE COMPANIES BLOCKBUSTER DRUGS CREATED NEW INDUSTRIES AND STANDARDS OF CARE MAIN BOARD: Sir Mare Feldmann and Dr Lawrence Steinman (Co-Chairmen) Dr Marlene Krauss (CEO) Dr Jonathan Rothbard
Slide 11: Fibrosis Program
FIBROSIS PROGRAM ical cli 1. Fibrosis represents major unmet me: needs 2. Further Dupuytren's trials (now Phase 28/3) if needed for EMA and FDA approval 3. Initiate Frozen Shoulder Trial 4, Initiate Post Operative Cog Dysfunction/ Delirium Trial 6. Preclinical CANNABINOID PROGRAM 4. Non psychoactive
Slide 12: Fibrotic Diseases
FIBROTIC DISEASES rof Sallie Lamt
Slide 13: Dupuytren's Disease Clinical Program
DUPUYTREN'S DISEASE CLINICAL PROGRAM ating disease with no approved therapeutic for early stage disease: Disease Progression Affects ~4% of population in USA and UK/Europe” Completed a dose ranging study in Phase 2a 2018, published Recruitment in progress for Phase 2b/3. + 181 participants in UK and
Slide 14: Estimated Future Worldwide Market for Dupuytren's >$1B per Year
Estimated future worldwide market for Dupuytren’s >$1B per year 800,000 US** 400,000 EU” 4 49 of the population of the US and EU 'O suffer from Dupuytren’s disease” 1% will be symptoma’ treatment eq Cost of injection Assumes 25% of ‘Assumes 25% will be £1,000 patients will be of symptomatic symptoma
Slide 15: Additional Clinical Indications
ADDITIONAL CLINICAL INDICATIONS FROZEN SHOULDER jul inflammatory condition that progresses to scarring, limiting movement Affects 2-9% of the population, more common in diabetics” Only treatment for early stage is local steroid injection for short term relief Phase 2 clinical trial planned for local
Slide 16: Foresight Years Before Bandwagon: Feldmann-Mechoulam Patent & Paper
FORESIGHT 20 YEARS BEFORE BANDWAGON: FELDMANN-MECHOULAM PATENT & PAPER “United States Patent Feldmann et al. () Patent NO.: US 6,410,588 B1 (5) Date of Patent: Jun. 25, 2002 (69 USE OF CANNABINOIDS AS ANTI-INFLAMMATORY AGENTS (75) Inventors: Marc Feldmann (London), Anne-Marie Malfait, Surrey, both o
Slide 17: v
v
Slide 18: Cannabinoid Project Initiated in 1998
$95 CANNBIORX CANNABINOID PROJECT WAS INITIATED IN 1998 WITH ISRAELI EXPERTS SEEKING ORALLY AVAILABLE ANTI-TNF AGENTS _ jue 000 2002-200 201 1 2019 2019 (BD effective ant New ark (CBR Pharma HU 436ppatent_ Prof AviDomb arthritis drug Malfait synthetic planforms inated in Canada issues. erusalem) - e
Slide 19: What Medical Unmet Needs Will Cannabinoids Address?
WHAT MEDICAL UNMET NEEDS WILL CANNABINOIDS ADDRESS? = Musculoskeletal (shoulder, knee, hands) >100’s million affected globally’ z + Neuropathic Treatment - cannabinoid in novel formulation/cannabinoid + other drug in novel formulation fi MULTIPLE ( + Paralysis, muscle spasm, weakness, eye problems p
Slide 20: What Is a7nAChR Program Doing That Is Unique in Inflammation?
WHAT IS a7NACHR PROGRAM DOING THAT IS UNIQUE IN INFLAMMATION? Target: a7nAChR: = essential receptor in the body's anti-inflammatory system controlled by the brain Repurposing drugs developed by large pharma that were safe, but unsuccessful for treating Alzheimer's Disease and Schizophrenia + None of
Slide 21: CannBioRx Goal
CANNBIORX GOAL: Identify and patent a CNS penetrant, orally available small molecule a7nAChR agonist Equally active as the biologics like anti-TNF Perhaps more effective because reduces multiple cytokines Activates body's natural anti-inflammatory pathway for a7nAChR Other targets: arthritis, multip
Slide 22: Summary of Patent Portfolio
SUMMARY OF PATENT PORTFOLIO HU 436 (Issued US) divisionals in progress CANNABINOID Others to be filed on new molecules and formulations Family At - Treatment early stage Dupuytren's disease Application Oct 12, 2017 Family A2 - Treating a localized fibrotic disorder using an IL-33 antagonist Applicat
Slide 23: What Are CannBioRx Priorities?
WHAT ARE CANNBIORX PRIORITIES? Developing its portfolio of safe and novel therapeutics in a cost-effective manner Enlarging its patent portfolio Continuing its novel clinical trial strategy: + Use of academic experts as trial leaders + Funding from public institutions (e.g. Welleome Trust) decreases
Slide 24: Why Is CannBioRx Destined to Be a Successful Company?
WHY IS CANNBIORX DESTINED TO BE A SUCCESSFUL COMPANY? KEY POINTS Global company: US, UK, Israel Diversified programs Cost-effective Go ES) Focus on huge therapeutic sector: Led by 3 pioneers Formed by integrating 3 companies sharing scientist: inflammation economies of scale * avoid redundancy = per
Slide 25: Conclusion
CANNBIORX CONCLUSION \ Unique investment at ___ Intersection of the cannabis N and biotech industries
Slide 26: References
REFERENCES 1 hp /nationalacademies.org/HMD/Reports/201/Relieving-Pain-in-Americe-A-lueprint-orTanaforming-Prevention-Care-Education-Researchaspx 2tis://uw.globenewswie.com/news-tlease/2018/09/21/1574244/0/en/Global-Pai-Menagement-Therapeutcs-Market Wil Reach-USO-79-500-Milion-by-2024-Zion-Market-Res
Slide 27: CannBioRx Life Sciences Corp
| CANNBIORX LIFE SCIENCES CORP Registered Address 1201 Orange Street Suite 600 Wilmington, DE 19801 USA CORPORATE HQ 4 Palo Alto Square 3000 El Camino Real Suite 200. Palo Alto, California 94306